The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

På svenska

Author

  • Stacy Loeb
  • Yasin Folkvaljon
  • Mats Lambe
  • David Robinson
  • Hans Garmo
  • Christian Ingvar
  • Pär Stattin

Summary, in English

The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the development of malignant melanoma. An increased risk of melanoma in sildenafil users was recently reported.

Department/s

Publishing year

2015

Language

English

Pages

2449-2455

Publication/Series

JAMA: The Journal of the American Medical Association

Volume

313

Issue

24

Document type

Journal article

Publisher

American Medical Association

Topic

  • Other Clinical Medicine

Status

Published

ISBN/ISSN/Other

  • ISSN: 1538-3598